Anvisa aprova novo medicamento oral para c�ncer de mama avan�ado

The approval by Anvisa for the new oral medication inluriyo (tosilato de inlunestranto) marks a significant breakthrough in the treatment of advanced breast cancer. This drug is now available for adults with locally advanced or metastatic breast cancer, providing a new option for patients who have limited treatment avenues. The approval underscores the ongoing advancements in cancer treatment and highlights the importance of regulatory bodies in bringing innovative therapies to patients in need. This development could lead to better outcomes and quality of life for many individuals battling this aggressive form of cancer.